The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Cellular energy metabolism is reprogrammed in cancer to fuel proliferation. In oncological therapy, treatment resistance remains an obstacle and is frequently linked to metabolic perturbations. Identifying metabolic changes as vulnerabilities opens up novel approaches for the prevention or targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Baier, Dina, Schoenhacker-Alte, Beatrix, Rusz, Mate, Pirker, Christine, Mohr, Thomas, Mendrina, Theresa, Kirchhofer, Dominik, Meier-Menches, Samuel M., Hohenwallner, Katharina, Schaier, Martin, Rampler, Evelyn, Koellensperger, Gunda, Heffeter, Petra, Keppler, Bernhard, Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875291/
https://www.ncbi.nlm.nih.gov/pubmed/35213972
http://dx.doi.org/10.3390/pharmaceutics14020238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875291/
https://www.ncbi.nlm.nih.gov/pubmed/35213972
http://dx.doi.org/10.3390/pharmaceutics14020238

Ejemplares similares